Recreational use of ketamine
- For general information on this drug, including medical usage, see ketamine.
Ketamine is a prescription anesthetic that is federally regulated (e.g., U.S. Schedule III, U.K. Class B) that functions as a dissociative anesthetic, and so has seen use as a recreational drug. Originating in the United States in the 1970s, the recreational use of ketamine has since spread to Europe, Canada, Asia, and Australia. Attempts are made to use the drug at sub-anesthetic doses; contexts for use include both private settings and at club venues (raves and parties), where it initially gained popularity. Despite its emergence as a club drug, users may eventually relegate their use to more private settings.
Ketamine interacts with a variety of other drugs, most pronounced with alcohol, opioids (potentiation), and barbiturates, and with drugs that increase blood pressure (e.g., stimulants, SNRI antidepressants, and especially MAOIs). The latter may have an additive effect on the user's blood pressure, causing tachycardia, palpitations and potentially serious arrhythmias.[not verified in body] Ketamine use as a recreational drug has been implicated in a small but greatly exaggerated number of annual deaths, the majority of which are youth or young adults, which have, taken together, led to increasing stringency of its regulation worldwide.
As a consequence of its drug interactions and adverse effects, including the ability to cause confusion and amnesia, and adverse reactions that occur during emergence from anaesthesia, some cases are known from the media that involved irresponsibly high dosages and accidents in people who were not prepared for the experience and/or took other drugs at the same time, despite ketamine being a physically very safe substance in comparison to other psychoactives like opioids or even alcohol. But ketamine can leave users vulnerable to date rape (i.e., because of the associated confusion and amnesia).
Due to the complexity of its chemical synthesis, ketamine supplies for recreation use must be diverted from licit medical sources, though there have been reports of industrial-scale illicit ketamine manufacture in China and India.
Recreational use of ketamine was documented in the early 1970s in underground literature (e.g. The Fabulous Furry Freak Brothers). It was used in psychiatric and other academic research through the 1970s, culminating in 1978 with the publishing of psychonaut John Lilly's The Scientist, and Marcia Moore and Howard Alltounian's Journeys into the Bright World, which documented the unusual phenomenology of ketamine intoxication. The incidence of non-medical ketamine use increased through the end of the century, especially in the context of raves and other parties. Its emergence as a club drug differs from other club drugs (e.g., MDMA), however, due to its anesthetic properties (e.g., slurred speech, immobilization) at higher doses; in addition, reports of ketamine being sold as "ecstasy" are common.
- United States
According to the ongoing Monitoring the Future study conducted by University of Michigan, prevalence rates of recreational ketamine use among American secondary school student (grades 8, 10, and 12) have varied between 0.8–2.5% since 1999, with recent rates at the lower end of this range. The 2006 National Survey on Drug Use and Health (NSDUH) reports a rate of 0.1% for persons ages 12 or older with the highest rate (0.2%) in those ages 18–25. Further, 203,000 people are estimated to have used ketamine in 2006, and an estimated 2.3 million people used ketamine at least once in their life. A total of 529 emergency department visits in 2009 were ketamine-related.
Cases of illicit ketamine use in club venues have been observed in the Czech Republic, France, Italy, Hungary, and the United Kingdom. Additional reports of use and dependence have been reported in Poland and Portugal.
Australia's 2010 National Drug Strategy Household Survey report shows a prevalence of recent ketamine use of 0.3% in 2004 and 0.2% in 2007 and 2010 in persons aged 14 or older.
Established by the Hong Kong Narcotics Division of the Security Bureau, the Central Registry of Drug Abuse (CRDA) maintains a database of all the illicit drug users who have come into contact with law enforcement, treatment, health care, and social organizations. The compiled data are confidential under the The Dangerous Drugs Ordinance of Hong Kong, and statistics are made freely available online on a quarterly basis. Statistics from the CRDA show that the number of ketamine users (all ages) in Hong Kong has increased from 1605 (9.8% of total drug users) in 2000 to 5212 (37.6%) in 2009. Increasing trends of ketamine use among illicit drug users under the age of 21 were also reported, rising from 36.9% of young drug users in 2000 to 84.3% in 2009.
A survey conducted among school-attending Taiwanese adolescents reported prevalence rates of 0.15% in 2004, 0.18% in 2005, and 0.15% in 2006 in middle-school (grades 7 and 9) students; in Taiwanese high-school (grades 10 and 12) students, prevalence was 1.13% in 2004, 0.66% in 2005, and 0.44% in 2006. From the same survey, a large portion (42.8%) of those who reported ecstasy use also reported ketamine use. Ketamine was the second most used illicit drug (behind ecstasy) in absconding Taiwanese adolescents as reported by a multi-city street outreach survey. In a study comparing the reporting rates between web questionnaires and paper-and-pencil questionnaires, ketamine use was reported a higher rate in the web version. Urine sampling at a club in Taipei, Taiwan showed high rates of ketamine use at 47.0%; this prevalence was compared with that of detainees suspected of recreational drug use in the general public, of which 2.0% of the samples tested positive for ketamine use.
Ketamine sold illicitly comes either from diverted legitimate supplies and semi-legitimate suppliers, or from theft of legitimate suppliers.
In 2003, the U.S. Drug Enforcement Administration conducted Operation TKO, a probe into the quality of ketamine being imported from Mexico. As a result of operation TKO, U.S. and Mexican authorities shut down the Mexico City company Laboratorios Ttokkyo, which was the biggest producer of ketamine in Mexico. According to the DEA, over 80% of ketamine seized in the United States is of Mexican origin. As of 2011, it was mostly shipped from places like India as cheap as $5/gram. The World Health Organization Expert Committee on Drug Dependence, in its thirty-third report (2003), recommended research into its recreational use due to growing concerns about its rising popularity in Europe, Asia, and North America.
In the 1993 book E for Ecstasy (about the uses of the street drug Ecstasy in the UK), the writer, activist, and Ecstasy advocate Nicholas Saunders highlighted test results showing that certain consignments of the drug also contained ketamine. Consignments of Ecstasy known as "Strawberry" contained what Saunders described as a "potentially dangerous combination of ketamine, ephedrine, and selegiline", as did a consignment of "Sitting Duck" Ecstasy tablets.
Liquid preparations of the drug are also becoming increasing common; users then apply a solution of the drug to cigarettes and allow them to dry, resulting in a prepared dose of the drug.
Ketamine's use as a recreational drug has contributed to more than 90 fatalities—the majority among young adults—in England and Wales in the years of 2005-2013, including accidental poisonings, drownings, and traffic accidents. This has led to its increasingly stringent regulation (e.g., upgrading ketamine from a Class C to a Class B banned substance in the U.K.).
Ketamine may increase the effects of other sedatives, including, but not limited to: alcohols, benzodiazepines, opioids, and barbiturates. Other drugs which increase blood pressure may interact with ketamine, having an additive effect on blood pressure; such agents include stimulants, SNRI antidepressants, and MAOIs. Increase blood pressure and heart rate, palpitations, and arrhythmias may be potential effects.
Ketamine is generally safe even for those critically ill, when administered by trained medical professionals. The dosages used recreationally are somewhat lower than a fully anaesthetic dosage, making the substance physically relatively safe in comparison to other psychoactive drugs. Still, even in these cases, there are known side effects that include one or more of the following:
- Cardiovascular: abnormal heart rhythms, slow heart rate or fast heart rate, high blood pressure or low blood pressure; and
- Central nervous system: increased intracranial pressure (ICP), leading to intracranial hypertension.
In addition there are dermatologic adverse reactions (ARs; transient erythema, transient morbilliform rash), gastrointestinal ARs (anorexia, nausea, increased salivation, vomiting), neuromuscular and skeletal ARs (Increased skeletal muscle tone, i.e., tonic-clonic movements), ocular ARs (double vision, increased intraocular pressure, nystagmus), respiratory ARs (airway obstruction, apnea, increased bronchial secretions, respiratory depression, laryngospasm), as well as local pain or exanthema (e.g., at injection sites) and possible anaphylaxis and dependence.
In 10-20% of patients at anesthetic doses, adverse reactions are experienced that occur during emergence from anesthesia, reactions that can manifest as seriously as hallucinations and delirium. These reactions may be less common in some patients subpopulations, and when administered intramuscularly, and can occur up to 24 hours postoperatively; the chance of this occurring can be reduced by minimizing stimulation to the patient during recovery and pretreating with a benzodiazepine, alongside a lower dose of ketamine. Patients who experience severe reactions may require treatment with a small dose of a short- or ultrashort-acting barbiturate.
|This section needs additional citations to secondary or tertiary sources (June 2015)|
Ketamine produces effects similar to phencyclidine (PCP) and dextromethorphan (DXM). Unlike these other well-known dissociatives, ketamine is very short-acting, its hallucinatory effects lasting tens of minutes when inhaled (insufflated) or injected, and hours when ingested. With ketamine, intensities of hallucinations are dose-dependent. Like other dissociative anaesthetics, hallucinations caused by ketamine are fundamentally different from those caused by serotonergic psychedelic (classic) hallucinogens.
The specific dissociative state produced by ketamine is characterised by a sense of detachment from one's physical body and the external world that is known as depersonalization and derealization.[non-primary source needed][better source needed] At sufficiently high doses, users may experience what is called the "K-hole", a state of extreme dissociation with phenomenology of schizophrenia (e.g., visual and auditory hallucinations).
John C. Lilly, Marcia Moore and D. M. Turner (amongst others) have written extensively about their own entheogenic use of and psychonautic experiences with ketamine. Both Moore and Turner died prematurely (due to hypothermia and drowning respectively) during presumed unsupervised ketamine use.
Detection of use
Ketamine may be quantitated in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest or to assist in a medicolegal death investigation. Blood or plasma ketamine concentrations are usually in a range of 0.5–5.0 mg/L in persons receiving the drug therapeutically (during general anesthesia), 1–2 mg/L in those arrested for impaired driving and 3–20 mg/L in victims of acute fatal overdosage. Urine is often the preferred specimen for routine drug use monitoring purposes. The presence of norketamine, a pharmacologically-active metabolite, is useful for confirmation of ketamine ingestion.
As the recreational dosages used are always below the fully anaesthetic threshold and thus lower than those medically administered, the term 'overdose' needs to be seen a bit differentiated from other drugs. While with continued use, people may build up some degree of tolerance, leading to the use of higher dosages than medically advised, it is technically somewhat difficult to overdose on ketamine. An even higher dosage will just lead to full anaesthesia, amnesia, but no physical danger from the drug itself as long as the environment isn't dangerous. The user will become catatonic when fully dissociated, not experiencing any pain but also unable to move his/her body.
There is no known effective antidote used to treat ketamine overdose, and treatment generally focuses on the maintenance of respiratory and circulatory function until the patient is capable of breathing under their own power and all cardiac abnormalities have subsided. Unlike many other anaesthetics, ketamine has a minimal effect on respiratory drive and tidal volume; while pulse oximetry is always essential it rarely drops enough to require mechanical ventilation or supplemental oxygen, except in the most massive of overdoses and in cases of mixed-drug-overdose.
Verbal reassurance and a calming environment (i.e. dim lights, calming music, and the presence of supportive individuals in the room) should be provided when possible to calm the patient and/or prophylacticly to prevent agitation. Occasionally it may become necessary to restrain highly agitated patients during recovery should they become violent, experience panic attacks, or otherwise present a threat to themselves or others.
Even after all vital signs have normalized and the patient appears functional it is advised to require the patient to be driven home as residual impairment of motor skills may persist for up to a day after apparent resolution.
|This section needs expansion. You can help by adding to it. (January 2012)|
Ketamine's potential for dependence has been established in various operant conditioning paradigms, including conditioned place preference and self-administration; further, rats demonstrate locomotor sensitization following repeated exposure to ketamine. Increased subjective feelings of 'high' have been observed in healthy human volunteers exposed to ketamine. Additionally, the rapid onset of effects following smoking, insufflation, and/or intramuscular injection is thought to increase the drug's recreational use potential. The short duration of effects promotes bingeing, tolerance can develop, and withdrawal symptoms, including anxiety, shaking, and palpitations, may be present in some daily users following cessation of use.
Due to its primary NMDA-antagonist effect, sudden withdrawal in severely addicted users will result in overexcitability, manifesting as increased sensitivity to stress, anxiety and pain. There are speculations about possible excitotoxicity resulting from the rebound surge in glutamate, but this has not yet been proven or disproven in humans and it doesn't seem to be a huge concern in healthy adults. Unlike GABAergic sedatives however, overexcitation secondary to ketamine withdrawal is not life-threatening as long as no underlying seizure disorders are present and even very tolerant users will likely suffer, at worst, only minor neurological sequela following the abrupt discontinuation of the drug. Some titration or the administration of anti-excitatory agents like memantine could be of benefit.
Ketamine can cause a variety of urinary tract problems that are more likely to occur with heavier and/or higher dosed use, especially in those not watching for a healthy lifestyle, according to a UK study.
Production for recreational use has been traced to 1967, when it was referred to as "mean green" and "rockmesc". Recreational names for ketamine include "K", "Kitty", "Kallie Ziltz", "Kartáč", "Ket", "Special K", "K2", "Vitamin K", "Super K", "Jet" (Texas), "Super acid", "Mauve", "Special LA coke", "Purple", "Cat Valium", "Knod-off", "Skittles", "Blind Squid", "Keller", "Kelly's Day", "New ecstasy", "Psychedelic heroin", "bump", "honey oil", "Majestic". A mixture of ketamine with cocaine is called "Calvin Klein" or "CK1". In Hong Kong, where illicit use of the drug is popular, ketamine is colloquially referred to as "kai-jai".
- "Reported drug abusers by age group by locality of abusing drugs" (PDF). Hong Kong Narcotics Division, Security Bureau. Retrieved 11 January 2012.
- Hayley Dixon, 2014, "Ketamine death of public schoolgirl an 'act of stupidity which destroyed family'," at The Telegraph (online), February 12, 2014, see , accessed 7 June 2015.
- The Crown, 2013, "Drug related deaths involving ketamine in England and Wales," a report of the Mortality team, Life Events and Population Sources Division, Office for National Statistics, the Crown (U.K.), see  and , accessed 7 June 2015.
- Marshall, Donnie R.; (Deputy Administrator); Drug Enforcement Administration; Dept. of Justice (13 July 1999). "Schedules of Controlled Substances: Placement of Ketamine into Schedule III [21 CFR Part 1308. Final Rule 99-17803]" (PDF). Rules and Regulations. Federal Register. 64 (133): 37673–5.
- Baker, Norman; (Minister for Crime Prevention); Home Office; United Kingdom (12 February 2014), Response to ACMD recommendation on ketamine (PDF) (Correspondence to Les Iverson [chair of]; Advisory Council on the Misuse of Drugs), Crown copyright; Open Government Licence, retrieved 21 February 2014.
- Dixon, Hayley (12 February 2014). "Party drug ketamine to be upgraded to Class B". The Daily Telegraph. Retrieved 2 August 2014.
- Woodard, D., "The Ketamine Necromance", in Apocalypse Culture II, ed. Parfrey, A. (Los Angeles: Feral House, 2000), pp. 288-295.
- Drugs.com. "Ketamine". Consumer Information. Retrieved 10 February 2014.
- "Do you know... Ketamine". Knowledge Exchange. Toronto: Centre for Addiction and Mental Health. 2003. Archived from the original on 2014-04-07. Retrieved 27 July 2014.
- "Ketamine". Center for Substance Abuse Research (CESAR); University of Maryland, College Park. 29 October 2013. Archived from the original on 2013-11-12. Retrieved 27 July 2014.
- "Transnational drug market analysis" (PDF). World Drug Report 2010. Retrieved 13 January 2012.
- Shelton, Gilbert (2008). The Freak Brothers Omnibus. London: Knockabout Comics. p. 144. ISBN 0-86166-159-1.
- Alltounian, Howard Sunny; Marcia Moore (1978). Journeys into the Bright World. Rockport, Mass.: Para Research. ISBN 0-914918-12-5.[page needed]
- Awuonda, Moussa (1 July 1996). "Swedes alarmed at ketamine misuse". The Lancet. 348 (9020): 122. doi:10.1016/S0140-6736(05)64628-4.
- Curran, HV; Morgan, C (April 2000). "Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later". Addiction. Abingdon, England. 95 (4): 575–90. doi:10.1046/j.1360-0443.2000.9545759.x. PMID 10829333.
- Gahlinger, PM (2004-06-01). "Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine". American Family Physician. 69 (11): 2619–26. PMID 15202696.
- Jansen, KL (1993-03-06). "Non-medical use of ketamine". BMJ (Clinical research ed.). 306 (6878): 601–2. doi:10.1136/bmj.306.6878.601. PMC . PMID 8461808.
- Joe-Laidler, Karen; Hunt, Geoffery (1 January 2008). "Sit Down to Float: The Cultural Meaning of Ketamine Use in Hong Kong". Addiction Research & Theory. 16 (3): 259–271. doi:10.1080/16066350801983673. PMC . PMID 19759834.
- Parker, Fiona Measham, Judith Aldridge, Howard (2001). Dancing on drugs: risk, health and hedonism in the British club scene. London: Free Association. ISBN 1-85343-512-0.
- Moore, Karenza; Measham, Fiona (1 January 2006). "Ketamine use: minimising problems and maximising pleasure". Drugs and Alcohol Today. 6 (3): 29–32. doi:10.1108/17459265200600047.
- "Trends in Use of Various Drugs, Table 2" (PDF). Monitoring the Future. Retrieved 17 January 2012.
- "Use of Specific Hallucinogens: 2006". The NSDUH Report. Substance Abuse and Mental Health Services Administration. Retrieved 17 January 2012.
- "Drug Abuse Warning Network, 2009: National Estimates of Drug-Related Emergency Department Visits." (PDF). HHS Publication No. (SMA) 11-4659, DAWN Series D-35. Substance Abuse and Mental Health Services Administration. Retrieved 17 January 2012.
- Kalsi, Sarbjeet S.; Wood, David M.; Dargan, Paul I. (15 April 2011). "The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use". Emerging Health Threats Journal. 4 (0). doi:10.3402/ehtj.v4i0.7107.
- Błachut, M; Sołowiów, K; Janus, A; Ruman, J; Cekus, A; Matysiakiewicz, J; Hese, RT (Sep–Oct 2009). "[A case of ketamine dependence].". Psychiatria polska. 43 (5): 593–9. PMID 20214100.
- Greenwald, Glenn. "Drug Decriminalization in Portugal" (PDF). CATO Institute. Retrieved 12 January 2012.
- "2010 National Drug Strategy Household Survey report". Australian Institute of Health and Welfare. Retrieved 11 January 2012.
- Cheung, Yuet. "DRUG POLICY AND HARM REDUCTION IN HONG KONG: A SOCIO-HISTORICAL EXAMINATION*" (PDF). Retrieved 12 January 2012.
- "CRDA Drug Statistics". Retrieved 12 January 2012.
- "CRDA Fifty-ninth Report (2000–2009)" (PDF). Retrieved 12 January 2012.
- Chen, Wei J; Fu, Tsung-Chieh; Ting, Te-Tien; Huang, Wei-Lun; Tang, Guang-Mang; Hsiao, Chuhsing; Chen, Chuan-Yu (1 January 2009). "Use of ecstasy and other psychoactive substances among school-attending adolescents in Taiwan: national surveys 2004–2006". BMC Public Health. 9 (1): 27. doi:10.1186/1471-2458-9-27.
- Wang, Shi-Heng; Wen-Chun Chen; Chih-Yin Lew-Ting; Chuan-Yu Chen; Wei J Chen (1 January 2010). "Running away experience and psychoactive substance use among adolescents in Taiwan: multi-city street outreach survey". BMC Public Health. 10 (1): 29. doi:10.1186/1471-2458-10-29.
- Wang, Yi-Ching; Ching-Mei Lee; Chih-Yin Lew-Ting; Chuhsing Kate Hsiao; Duan-Rung Chen; Wei J. Chen (1 October 2005). "Survey of substance use among high school students in Taipei: Web-based questionnaire versus paper-and-pencil questionnaire". Journal of Adolescent Health. 37 (4): 289–295. doi:10.1016/j.jadohealth.2005.03.017.
- Lua, Ahai Chang; Lin, Huei Ru; Tseng, Yong Te; Hu, An Ren; Yeh, Pei Chi (1 September 2003). "Profiles of urine samples from participants at rave party in Taiwan: prevalence of ketamine and MDMA abuse". Forensic Science International. 136 (1-3): 47–51. doi:10.1016/S0379-0738(03)00261-5.
- "SI.com - The Mexican Connection - Jul 18, 2007". CNN. Retrieved 7 May 2010.
- Saunders N, Heron L (1993). E for Ecstasy. London: N. Saunders. ISBN 0-9501628-8-4.[page needed]
- See:  for details online.
- Hui, TW; Short, TG; Hong, W; Suen, T; et al. (March 1995). "Additive interactions between propofol and ketamine when used for anesthesia induction in female atients". Anesthesiology. 82 (3): 641–8. doi:10.1097/00000542-199503000-00005. PMID 7879932.
- Hong, W; Short, TG; Hui, TW (December 1993). "Hypnotic and anesthetic interactions between ketamine and midazolam in female patients". Anesthesiology. 79 (6): 1227–32. doi:10.1097/00000542-199312000-00013. PMID 8267198.
- Akhavanakbari, G; Mohamadian, A; Entezariasl, M (April 2014). "Evaluation the effects of adding ketamine to morphine in intravenous patient-controlled analgesia after orthopedic surgery". Perspectives in Clinical Research. 5 (2): 85–7. doi:10.4103/2229-3485.128028. PMC . PMID 24741486.
- Eker, HE; Yalcin Cok, O; Aribogan, A; Arslan, G (October 2011). "Children on phenobarbital monotherapy requires more sedatives during MRI". Pediatric Anesthesia. 21 (10): 998–1002. doi:10.1111/j.1460-9592.2011.03606.x. PMID 21564387.
- Cohen, L; Athaide, V; Wickham, ME; Doyle-Waters, MM; Rose, NG; Hohl, CM (January 2015). "The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review.". Annals of Emergency Medicine. 65 (1): 43–51.e2. doi:10.1016/j.annemergmed.2014.06.018. PMID 25064742.
- Merck Manual; Drug Information Provided by Lexi-Comp. Last full review/revision May 2014 Ketamine
- Wang, Xin; Ding, Xibing; Tong, Yao; Zong, Jiaying; Zhao, Xiang; Ren, Hao; Li, Quan (24 May 2014). "Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials". Journal of Anesthesia. 28: 7. doi:10.1007/s00540-014-1845-3.
- Quibell, R; Prommer, EE; Mihalyo, M; Twycross, R; et al. (March 2011). "Ketamine*". Journal of Pain and Symptom Management (Therapeutic Review). 41 (3): 640–9. doi:10.1016/j.jpainsymman.2011.01.001. PMID 21419322.
- Strayer, RJ; Nelson, LS (2008). "Adverse events associated with ketamine for procedural sedation in adults". American Journal of Emergency Medicine. 26 (9): 985–1028. doi:10.1016/j.ajem.2007.12.005. PMID 19091264.
- Giannini AJ, Loiselle RH, Giannini MC, Price WA (1985). "Phencyclidine and the dissociatives". Psychiatric Medicine. 3 (3): 197–217. PMID 2893430.
- AJ Giannini; RH Loisellle; MC Giannini; WA Price (1987). "The dissociatives". Medical Psychiatry. 3 (3): 197–205.
- Giannini AJ, Underwood NA, Condon M (November 2000). "Acute ketamine intoxication treated by haloperidol: a preliminary study". American Journal of Therapeutics. 7 (6): 389–91. doi:10.1097/00045391-200007060-00008. PMID 11304647.[non-primary source needed][better source needed]Template:Primary source-nline
- Giannini, AJ (1999). Drug Abuse. Los Angeles: Health Information Press. p. 104. ISBN 1885987110.
- Lilly, John Cunningham (1997). The scientist: a metaphysical autobiography. Berkeley, CA: Ronin Pub. ISBN 0-914171-72-0.[page needed]
- Alltounian, Howard Sunny; Marcia Moore (1978). Journeys into the bright world. Rockport, Mass: Para Research. ISBN 978-0-914918-12-7.[page needed]
- Turner, D. M. (1994). The essential psychedelic guide. San Francisco, CA: Panther Press. ISBN 0-9642636-1-0.[page needed]
- A further reference regarding recreational use is:Palmer, Cynthia; Horowitz, Michael (2000). Sisters of the Extreme: Women Writing on the Drug Experience. Inner Traditions. pp. 254–8, ibid. ISBN 9780892817573.
- Jansen, Karl (2001). Ketamine: Dreams and Realities. Multidisciplinary Association for Psychedelic Studies. pp. 50, 89. ISBN 0966001931.
- Feng N, Vollenweider FX, Minder EI, Rentsch K, Grampp T, Vonderschmitt DJ. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther. Drug Monit. 17: 95–100, 1995.
- Parkin MC, Turfus SC, Smith NW, Halket JM, Braithwaite RA, Elliott SP, Osselton MD, Cowan DA, Kicman AT. Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry. J. Chrom. B 876: 137–142, 2008.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 806–808.
- Maxwell, Jane C. "IMPLICATIONS OF RESEARCH FOR TREATMENT: KETAMINE" (PDF). THE CENTER FOR EXCELLENCE IN DRUG EPIDEMIOLOGY. University of Texas at Austin. p. 3. Retrieved 10 February 2014.
- Nutt D, King LA, Saulsbury W, Blakemore C (2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831.
- Morgan, Celia J. A.; Curran, H. Valerie (1 January 2012). "Ketamine use: a review". Addiction. 107 (1): 27–38. doi:10.1111/j.1360-0443.2011.03576.x. PMID 21777321.
- Jansen, Karl (2001). Ketamine: Dreams and Realities. Multidisciplinary Association for Psychedelic Studies. p. 24. ISBN 0-9660019-3-1.
- Jansen, Karl (2001). Ketamine: Dreams and Realities. Multidisciplinary Association for Psychedelic Studies. p. 26. ISBN 0-9660019-3-1.
- "Center for Substance Abuse Research: Ketamine Terminology". Retrieved 3 January 2012.
- Jansen, Karl (2001). Ketamine: Dreams and Realities. Multidisciplinary Association for Psychedelic Studies. p. 55. ISBN 0-9660019-3-1.
- "DEA Office of Diversion Control: Ketamine". Retrieved 3 January 2012.
- "Ketamine: A fact sheet (National Clearinghouse for Alcohol and Drug Information)" (PDF). Retrieved 3 January 2012.
- Tellier, PP (September 2002). "Club drugs: is it all ecstasy?". Pediatric annals. 31 (9): 550–6. doi:10.3928/0090-4481-20020901-07. PMID 12271739.
- "Research Report on Hallucinogens and Dissociatives" (PDF). NIDA. Retrieved 11 January 2012.
- Nutt, David (2012). Drugs - Without the Hot Air: Minimising the Harms of Legal and Illegal Drugs. UIT Cambridge. ISBN 1906860165.
- Chakraborty, K; Neogi, R; Basu, D (June 2011). "Club drugs: review of the 'rave' with a note of concern for the Indian scenario.". The Indian journal of medical research. 133 (6): 594–604. PMC . PMID 21727657.